1) A royalty is more valuable then a percent interest since there are no expenses.
2) If you get a good partner (actually in Clinuvels case a so-so partner with Regulatory/commercial experience) they would advance the program/commercialize at a faster rate so there is a time/value associated with that. The track record of Clinuvel is extremely slow on developing, regulatory and now commercialization.
3) Without a partner they are either going to go extremely slow with Vitiligo and/or dilute a fair amount. My guess with chronic treatment in a fairly large disease indication they will need to well controlled studies with perhaps a thousand (or more) patients and then some descent long term safety. If you take an estimate of 50k/yr per patient in trial that could be 100m+ for 2 years of development.
IMO, I don't get the sense they'll get a top tier partner they need a better formulation and don't have a lot of data on Vitiligo to get someone overly excited at this point. The singapore study was another example of terrible execution of the company.
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM